(Q46230471)

English

Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients

scientific article published on 22 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

author name string

Andrew R Pachner

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

Jennifer Brady

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

Israel Steiner

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

Kavitha Narayan

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

publication date

22 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

255

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

1815-1817

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

https://scigraph.springernature.com/pub.10.1007/s00415-008-0854-2

0 references

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0854-2

21 January 2018

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0854-2

21 January 2018

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing anti-IFNbeta antibodies: clarity and confusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-IFN BAb and NAb antibodies: a minireview

1 reference

https://pubmed.ncbi.nlm.nih.gov/19031099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-008-0854-2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19031099

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46230471&oldid=2100549339"